Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended vs Standard Interval Immunotherapy Maintenance in Advanced TNBC
NCT07401537Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in triple-negative breast cancer (TNBC) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started Dec 2025; status: recruiting.
02
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07401537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07401537.